These promotional videos were funded by Accord Healthcare Ltd. and are intended for healthcare professionals only.
Prescribing information and adverse event reporting information can be found at the bottom of this page.
The four video interviews were recorded at PROSCA 2024 in Vienna. These videos explore oral Androgen deprivation therapy (ADT) treatment and impact this treatment option has on treating advanced prostate cancer and which patients could benefit. The Summary of Product Characteristics and/or Prescribing Information for all the products discussed during the Vidoes can be found below:
The summary of product characteristics and/or prescribing information for all the products discussed during the videos can be found below.
Orgovyx▼(relugolix) UK prescribing information can be found here.
Orgovyx▼(relugolix) EU prescribing information can be found here.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
| Adverse events should be reported. For UK healthcare professionals, reporting forms, and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Accord-UK LTD on 01271 385257 or [email protected]. For non-UK/EU healthcare professionals, you can report side effects directly via the national reporting system listed in Appendix V of the EU SmPC. |
The recording of this promotional symposium took place at PROSCA 2024 in Vienna, and presents highlights across a variety of areas involved in diagnosis and treatment in Prostate Cancer. The products mentioned in this session may not be registered in all countries. Prescribing information may vary per country. Healthcare professionals must refer to their country prescribing information. This promotional video is intended for an international audience of Healthcare professionals.
| Adverse events should be reported. For UK healthcare professionals, reporting forms, and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Accord-UK LTD on 01271 385257 or [email protected]. For non-UK/EU healthcare professionals, you can report side effects directly via the national reporting system listed in Appendix V of the EU SmPC. |
EUR-Onc-Org-01546 | April 2025
